statistiche ricercatore

Continente	#
NA - Nord America	688
AS - Asia	329
EU - Europa	180
SA - Sud America	47
AF - Africa	9
Continente sconosciuto - Info sul continente non disponibili	2
OC - Oceania	2
Totale	1.257

Nazione	#
US - Stati Uniti d'America	679
SG - Singapore	131
HK - Hong Kong	70
CN - Cina	65
SE - Svezia	45
BR - Brasile	36
GB - Regno Unito	36
VN - Vietnam	34
RU - Federazione Russa	22
DE - Germania	21
FI - Finlandia	13
BG - Bulgaria	10
FR - Francia	8
AR - Argentina	7
ID - Indonesia	7
IT - Italia	7
CA - Canada	6
IN - India	6
NL - Olanda	6
TR - Turchia	4
ZA - Sudafrica	4
AE - Emirati Arabi Uniti	3
SA - Arabia Saudita	3
UA - Ucraina	3
A2 - ???statistics.table.value.countryCode.A2???	2
AU - Australia	2
BD - Bangladesh	2
IE - Irlanda	2
JP - Giappone	2
MA - Marocco	2
MX - Messico	2
PT - Portogallo	2
AT - Austria	1
CL - Cile	1
CO - Colombia	1
EC - Ecuador	1
EG - Egitto	1
ES - Italia	1
IQ - Iraq	1
JM - Giamaica	1
KE - Kenya	1
MD - Moldavia	1
MK - Macedonia	1
NO - Norvegia	1
PH - Filippine	1
PY - Paraguay	1
TN - Tunisia	1
Totale	1.257

Nome	#
Clinical and serological profile of primary biliary cirrhosis in men	153
Clinical Impact and behaviour of serum autoantibodies in adult liver transplantation	137
Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis	137
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis	137
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways	122
De novo autoimmune hepatitis in liver transplant: State-of-the-art review	121
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants	119
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score	119
Pathway-based analysis of primary biliary cirrhosis genome-wide association studies	117
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program	111
Totale	1.273

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	90	0	0	0	0	0	0	0	0	51	0	38	1
2021/2022	169	29	8	10	8	0	4	4	14	23	22	24	23
2022/2023	215	32	24	19	23	22	40	1	20	20	1	8	5
2023/2024	109	1	10	5	22	27	1	20	7	2	2	0	12
2024/2025	369	7	2	4	27	81	60	13	26	61	9	21	58
2025/2026	321	51	17	36	64	128	25	0	0	0	0	0	0
Totale													1.273